Summary

Critical Care, Hemodynamic Ultrasound, Patient Management, Hemodynamic Monitoring, Fluid Management, ICU, CTICU, CICU, SICU, NICU, MICU, ER, ED, High Acuity Care, High Risk Patients, MCS, ECMO, Image Guidance, TEE Monitoring, Intensive Care, hTEE, Dynamic TEE, Direct Visualization, Preload, Contractility, Monitoring, Sepsis, High Risk Surgery, Support, ClariTEE probe, 72-hr indwelling probe, Zura Handheld, One Touch Hemodynamics

Industry

Description

ImaCor's Hemodynamic Ultrasound Platform combines imaging and monitoring in a portable package for ease-of-use by high acuity care teams. The result --- lifesaving course corrections in as much as 70% of patients vs standard of care. ImaCor’s miniaturized transesophageal ultrasound probe, the ClariTEE, is FDA approved to be left in place for up to 72 hours, enabling direct visualization in the ICU of cardiac filling and function over time. The patented probe has been used in over 20,000 patients with no complications. ImaCor’s Hemodynamic Ultrasound Platform provides preload and contractility data for rapid decision making, transforming care for sepsis, surgery, and cardiac support patients.

Special details

ClariTEE Probe - a single patient use, miniaturized, disposable transesophageal echocardiography (TEE) probe that can be left indwelling for up to 72 hours to monitor cardiac filling and function; Zura Handheld - an app-based, handheld ultrasound system that exclusively powers the ClariTEE probe; connects wirelessly to app-based Android and iOS mobile devices

Profile

  • Incorporated in
    Delaware
  • Established since
    2003
  • Main/Branch
    Branch

Address

Contact